is for sale

Friday, January 20, 2012

HIV-AIDS Testing Market to Explode to $4.4 Billion by 2016

January 11, 2012 13:00 ET

NEW YORK, NY--(Marketwire - Jan 11, 2012) - cites in its newly published "HIV-AIDS Testing Markets" report that the global HIV-AIDS testing market is forecasted to catapult to $4.4 billion by 2016. For more information, visit:

HIV-AIDS testing can be categorized into six main modalities: predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic. There are an estimated 33.3 million people living with HIV worldwide and approximately 2.6 million people are newly infected each year. Although the Asian and African regions account for more than 90% of the HIV-infected population, the U.S. and European regions make up greater than 60% of the HIV testing market.

The "HIV-AIDS Testing Markets" report covers:
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Antibody/p24 Antigen Test (Fourth-Generation Test)
  • Western Blot Assay
  • Line Immunoassays
  • Indirect Fluorescent Antibody (IFA) Assay
  • Nucleic Acid Tests for Infectious Diseases
  • Emerging Technologies
The "HIV-AIDS Testing Markets" report examines companies manufacturing HIV/AIDS testing equipment and supplies in the world. Companies covered include: Abbott, Alere, Ani, Avioq, Bio-Rad, bioLytical, Biomedical, bioMerieux, Bioner, Chembio, Core, EY, Gen-Probe, Green Cross, Immunoscience, InTec, J Mitra, Maxim, MedMira, Oral Collection Devices, OraSure, Orgenics, Ortho-Clinical, Premier, Qiagen, Qualpro, Roche, Savyon, Shanghai Kehua, Siemens, Span, Standard and Trinity.

Detailed charts with sales forecasts and marketshare data are included. For more information, visit:

About is a global leader in the biotechnology, healthcare and life sciences market research publishing. For more information, please visit
Important Notice
The statements contained in this news release that are forward-looking are based on current expectations that are subject to a number of uncertainties and risks, and actual results may differ materially.

Contact Information

Media Relations
Enhanced by Zemanta

No comments:

Post a Comment